204 related articles for article (PubMed ID: 17145606)
21. Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colony-stimulating factor in sickle cell disease.
Conran N; Saad ST; Costa FF; Ikuta T
Ann Hematol; 2007 Apr; 86(4):255-61. PubMed ID: 17205286
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.
Wiczling P; Liem RI; Panepinto JA; Garg U; Abdel-Rahman SM; Kearns GL; Neville KA
J Clin Pharmacol; 2014 Sep; 54(9):1016-22. PubMed ID: 24729271
[TBL] [Abstract][Full Text] [Related]
23. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of clinical response by hydroxyurea in 132 patients with major sickle cell anemia].
Elira Dokekias A; Okandze Elenga JP; Ndinga J; Sanogo I; Sangare A
Tunis Med; 2005 Jan; 83(1):32-7. PubMed ID: 15881719
[TBL] [Abstract][Full Text] [Related]
25. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.
Bachir D; Hulin A; Huet E; Habibi A; Nzouakou R; El Mahrab M; Astier A; Galacteros F
Hemoglobin; 2007; 31(4):417-25. PubMed ID: 17994375
[TBL] [Abstract][Full Text] [Related]
26. Do difficulties in swallowing medication impede the use of hydroxyurea in children?
Bekele E; Thornburg CD; Brandow AM; Sharma M; Smaldone AM; Jin Z; Green NS
Pediatr Blood Cancer; 2014 Sep; 61(9):1536-9. PubMed ID: 24753149
[TBL] [Abstract][Full Text] [Related]
27. Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease.
Odièvre MH; Bony V; Benkerrou M; Lapouméroulie C; Alberti C; Ducrocq R; Jacqz-Aigrain E; Elion J; Cartron JP
Haematologica; 2008 Apr; 93(4):502-10. PubMed ID: 18322255
[TBL] [Abstract][Full Text] [Related]
28. Ten-year review of hospital admissions among children with sickle cell disease in Kuwait.
Akar NA; Adekile A
Med Princ Pract; 2008; 17(5):404-8. PubMed ID: 18685282
[TBL] [Abstract][Full Text] [Related]
29. Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation.
Boucher AA; Dong M; Vinks AA; Marahatta A; Howard TA; Ware RE; Nathan JD; Abu-El-Haija M; Luchtman-Jones L
J Clin Pharmacol; 2021 Apr; 61(4):547-554. PubMed ID: 33029796
[TBL] [Abstract][Full Text] [Related]
30. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
31. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.
Lanzkron S; Haywood C; Segal JB; Dover GJ
Am J Hematol; 2006 Dec; 81(12):927-32. PubMed ID: 16924648
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R
Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107
[TBL] [Abstract][Full Text] [Related]
33. Sickle cell pain & hydroxyurea.
Day SW; Wynn LW
Am J Nurs; 2000 Nov; 100(11):34-8; quiz 38-9. PubMed ID: 11103633
[No Abstract] [Full Text] [Related]
34. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy.
O'branski EE; Ware RE; Prose NS; Kinney TR
J Am Acad Dermatol; 2001 May; 44(5):859-61. PubMed ID: 11312437
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets.
Breier AR; Paim CS; Steppe M; Schapoval EE
J Pharm Pharm Sci; 2005 Aug; 8(2):289-98. PubMed ID: 16124939
[TBL] [Abstract][Full Text] [Related]
36. Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.
Estepp JH; Wiczling P; Moen J; Kang G; Mack JM; Liem R; Panepinto JA; Garg U; Kearns G; Neville KA
Br J Clin Pharmacol; 2018 Jul; 84(7):1478-1485. PubMed ID: 28884840
[TBL] [Abstract][Full Text] [Related]
37. Chemical and functional analysis of generic hydroxyurea formulations.
Harrod VL; Howard T; Abboud MR; Hankins J; Lobo C; Ware RE
Pediatr Hematol Oncol; 2008 Jun; 25(5):423-9. PubMed ID: 18569844
[TBL] [Abstract][Full Text] [Related]
38. Use of hydroxyurea from childhood to adult age in sickle cell disease: semen analysis.
Lukusa AK; Vermylen C
Haematologica; 2008 Nov; 93(11):e67; discussion e68. PubMed ID: 18978293
[No Abstract] [Full Text] [Related]
39. Comparing abstract numerical and visual depictions of risk in survey of parental assessment of risk in sickle cell hydroxyurea treatment.
Patterson CA; Barakat LP; Henderson PK; Nall F; Westin A; Dampier CD; Hsu LL
J Pediatr Hematol Oncol; 2011 Jan; 33(1):4-9. PubMed ID: 21178705
[TBL] [Abstract][Full Text] [Related]
40. Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean countries.
Svarch E; Machín S; Nieves RM; Mancia de Reyes AG; Navarrete M; Rodríguez H
Pediatr Blood Cancer; 2006 Jul; 47(1):111-2. PubMed ID: 16550531
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
